Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

U.S. TCM Company Acquires Chinese Firm’s Product Line

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China Sky One Medical will pay $8.3 million to Heilongjiang Tianlong Pharmaceutical, for the acquisition of Tianlong Pharmaceutical

You may also be interested in...



China Sky One Reports 140 Percent Increase In Revenue, Lists on American Stock Exchange

BEIJING - China Sky One Medical reported first quarter revenue of $12.4 million, marking a 140 percent increase year on year, the company told a May 15 earnings call

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

Table

View full table

Tags:
Latest Headlines

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

Sanofi Skates To Where The Puck Is With Immunology

Pipeline Watch: Five Approvals And 23 Phase III Updates

Metsera Launches As New Obesity Contender Flush With $290m

See All
UsernamePublicRestriction

Register

SC067884

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By